Related Experiment Video
Updated: Jun 6, 2025

Methyl-binding DNA capture Sequencing for Patient Tissues
Published on: October 31, 2016
RNA methylation and breast cancer: insights into m6A, m7G and m5C
Yuhan Dai1, Shuhan Zhao1, Huilin Chen1
1Department of breast surgery, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Abstract:
Breast cancer remains the most commonly diagnosed cancer in female worldwide, marked by its molecular diversity and complex subtypes. Despite progress in targeted therapies, tumor heterogeneity and treatment resistance continue to present major challenges. Recent studies emphasize the crucial role of RNA modifications in cancer biology, with nearly 200 distinct modifications identified. Among these, methylation is particularly significant, with methylation-related factors emerging as key regulators of RNA metabolism, influencing cancer progression, metastasis, and treatment resistance. This review focuses on the roles of key RNA methylation in breast cancer, particularly N6-methyladenosine (m6A), N7-methylguanosine (m7G), 5-methylcytosine (m5C), N1-methyladenosine (m1A), and N3-methylcytidine (m3C). We examine the functions of m6A "writers" like METTL3 and METTL14, and "readers" such as the YTH domain family in modulating tumor behavior. Dysregulation of m6A "erasers" like FTO and ALKBH5 are noticed too, highlighting their impact on cancer stem cell phenotypes, chemoresistance, and immune evasion. Additionally, the role of m7G modifications in mRNA stability and translation, facilitated by METTL1/WDR4 and RNMT, is discussed as a potential therapeutic target. The involvement of m5C, m1A, and m3C modifications, particularly those mediated by NSUN2 and NSUN6, in breast cancer tumorigenesis and prognosis is also reviewed. Despite coding RNAs, the interplay between these RNA methylations and non-coding RNAs, such as lncRNAs and miRNAs, is explored, shedding light on their roles in cancer cell proliferation, invasion, and immune response modulation. This review highlights the potential of RNA methylations as novel therapeutic targets in breast cancer, offering insights for precision medicine and improved patient outcomes.
Insights
RNA modifications, especially methylation (m6A, m7G, m5C), are key in breast cancer progression and resistance. Targeting these RNA methylation regulators offers new avenues for precision medicine and improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Breast cancer exhibits molecular diversity, posing challenges in treatment due to heterogeneity and resistance.
- RNA modifications are increasingly recognized as critical regulators in cancer biology.
- Methylation, a key RNA modification, influences cancer progression, metastasis, and treatment resistance.
Purpose of the Study:
- To review the roles of key RNA methylations in breast cancer.
- To examine the functions of RNA methylation "writers," "readers," and "erasers."
- To explore the therapeutic potential of targeting RNA methylation in breast cancer.
Main Methods:
- Literature review focusing on RNA methylation in breast cancer.
- Analysis of the roles of specific RNA methylation types (m6A, m7G, m5C, m1A, m3C) and their associated proteins.
- Exploration of the interplay between RNA methylation and non-coding RNAs.
Main Results:
- N6-methyladenosine (m6A) modifications, regulated by METTL3, METTL14, FTO, and ALKBH5, impact tumor behavior, stem cell phenotypes, chemoresistance, and immune evasion.
- N7-methylguanosine (m7G) modifications influence mRNA stability and translation, presenting a therapeutic target.
- Other methylations (m5C, m1A, m3C) and their interplay with non-coding RNAs are implicated in breast cancer tumorigenesis and prognosis.
Conclusions:
- RNA methylations are crucial in breast cancer development and progression.
- Dysregulation of RNA methylation pathways contributes to treatment resistance and immune evasion.
- Targeting RNA methylation pathways presents a promising strategy for novel breast cancer therapies and precision medicine.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
RNA Stability
Master Transcription Regulators

